Neurocognition with maraviroc compared with tenofovir in HIV.

ABSTRACT:

Objective

The objective was to determine whether maraviroc (MVC) has unique neurocognitive benefits in the context of initial antiretroviral therapy (ART).

Design

Randomized, double-blind, placebo-controlled, 48-week trial.

Setting

Participants were enrolled in US AIDS Clinical Trials Group clinical trial sites.

Participants

Total 262 ART-naive, chemokine coreceptor 5 tropic HIV, and HIV RNA greater than 1000 copies/ml participants were randomized, 230 participants completed the study.

Intervention

Participants received MVC 150 mg or tenofovir disoproxil fumarate (TDF) 300 mg on a background of ritonavir-boosted darunavir and emtricitabine.

Main outcome measure(s)

The neuropsychological battery of 15 tests done at baseline, week 24 and week 48 ass

SUBMITTER: Robertson KR 

PROVIDER: S-EPMC5014739 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature